ALPS Advisors’s Atossa Therapeutics ATOS Stock Holding History

ALPS Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,676	Closed	-$163K	–	1034
2022 Q1	$163K	Sell	8,676 -1,093	-11%	-$22.2K	﹤0.01%	814
2021 Q4	$234K	Buy	+9,769	New	+$357K	﹤0.01%	864

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ALPS Advisors's ATOS Position: Q2 2022 in Review

ALPS Advisors sold out of Atossa Therapeutics (ATOS) in Q2 2022, closing a stake of 8,676 shares — an estimated $163K sold.

ALPS Advisors first reported a position in ATOS in Q4 2021 and held it in 2 quarters. The position peaked at $234K in Q4 2021. 73 funds tracked by Wall St. Rank hold ATOS as of Q2 2022.

ALPS Advisors reported no remaining Atossa Therapeutics position as of Q2 2022 after selling out during the quarter.
ALPS Advisors sold 8,676 Atossa Therapeutics shares in Q2 2022, an estimated $163K.
ALPS Advisors first reported a position in Atossa Therapeutics in Q4 2021 and held it in 2 quarters.
ALPS Advisors's Atossa Therapeutics position peaked at $234K in Q4 2021.
73 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.